Source | Match | ReputationScore* |
---|---|---|
RIO
Collection of samples and data across the following diseases: Malignant tumour of breast Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
|
|
*ReputationScore indicates how established a given datasource is. Find out more.